Biovitrum's Annual Report and Business Review for 2006
Biovitrum AB (publ) announced today that the company's complete Annual Report
for 2006 is now available as a PDF document for downloading or reading at
www.biovitrum.com. A Business Review with condensed accounting data is also
available as a PDF document. A printed version of the Business Review will be
distributed to the share holders in the next few days.
Biovitrum's Annual General Meeting will be held May 3, 2007.
For additional information, please contact:
Biovitrum AB (publ)
Anders Martin-Löf, Director Investor Relations
Phone: +46 8 697 37 07, cell phone: +46 70 624 32 56
anders.martin-lof@biovitrum.com
Anna Karin Källén, Vice President, Corporate Communications
Phone: +46 8 697 20 85, cell phone: +46 73 433 20 85
annakarin.kallen@biovitrum.com
About Biovitrum
Biovitrum is one of the largest biopharma companies in Europe. With operations
in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals
for unmet medical needs both for common diseases and conditions that affect
smaller patient populations. Biovitrum has a broad and balanced R&D portfolio
with several projects in clinical and preclinical phases for the treatment of
obesity, diabetes, inflammation and eye and blood diseases as well as a number
of well defined niche indications. Biovitrum develops and produces protein-based
drugs on a contractual basis and markets a range of specialist pharmaceuticals
primarily in the Nordic countries. Biovitrum has revenues of approximately SEK
1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock
Exchange since September 15, 2006. For more information see www.biovitrum.com.
